Role of the fibroblast growth factor receptor axis in cholangiocarcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 7, 2015, Pages 1116-1122

  Ang, Celina ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cholangiocarcinoma; Fibroblast growth factor receptor; Tyrosine kinase inhibitor

Indexed keywords

BRIVANIB; CAPECITABINE; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 5; GEMCITABINE; INFIGRATINIB; LENVATINIB; NINTEDANIB; ORANTINIB; PAZOPANIB; PONATINIB; REGORAFENIB; 3-(2,6-DICHLORO-3,5-DIMETHOXYPHENYL)-1-(6-(4-(4-ETHYLPIPERAZIN-1-YL)-PHENYLAMINO)PYRIMIDIN-4-YL)-1-METHYLUREA; ALANINE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; FGFR2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; TRIAZINE DERIVATIVE;

BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; HEPATOBILIARY SYSTEM CANCER; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CHROMOSOME ABERRATION; DRUG DEVELOPMENT; GENE FUSION; GENETICS; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY;

ALANINE; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; CHROMOSOME ABERRATIONS; DRUG DISCOVERY; GENE FUSION; HUMANS; MOLECULAR TARGETED THERAPY; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION; TRIAZINES;

EID: 84931075580     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12916     Document Type: Review

References (75)

1. American Cancer Society. Bile duct cancer (cholangiocarcinoma). 2013 American Cancer Society: Atlanta, Georgia.
2. Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin. Gastroenterol. Hepatol. 2013; 11: 13-21.e1; quiz e3-4.
3. Zabron A, Edwards RJ, Khan SA. The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis. Model Mech. 2013; 6: 281-292.
4. Maemura K, Natsugoe S, Takao S. Molecular mechanism of cholangiocarcinoma carcinogenesis. J. Hepatobiliary Pancreat. Sci. 2014; 21: 754-760.
5. Woo HG, Lee JH, Yoon JH etal. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res. 2010; 70: 3034-3041.
6. Ito T, Sakurai-Yageta M, Goto A, Pairojkul C, Yongvanit P, Murakami Y. Genomic and transcriptional alterations of cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 2014; 21: 380-387.
7. Jang S, Chun SM, Hong SM etal. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases. Mod. Pathol. 2014; 27: 731-739.
8. Borad MJ, Champion MD, Egan JB etal. Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014; 10: e1004135.
9. Borger DR, Tanabe KK, Fan KC etal. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist 2012; 17: 72-79.
10. McKay SC, Unger K, Pericleous S etal. Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma. HPB (Oxford) 2011; 13: 309-319.
11. Li L, Lian B, Li C etal. Integrative analysis of transcriptional regulatory network and copy number variation in intrahepatic cholangiocarcinoma. PLoS One 2014; 9: e98653.
12. Hezel AF, Deshpande V, Zhu AX. Genetics of biliary tract cancers and emerging targeted therapies. J. Clin. Oncol. 2010; 28: 3531-3540.
13. Tannapfel A, Sommerer F, Benicke M etal. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut 2003; 52: 706-712.
14. Goldenberg D, Rosenbaum E, Argani P etal. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod. Pathol. 2004; 17: 1386-1391.
15. Zen Y, Harada K, Sasaki M etal. Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-beta1 by overexpression of cyclin D1. Lab. Invest. 2005; 85: 572-581.
16. DeOliveira ML, Cunningham SC, Cameron JL etal. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 2007; 245: 755-762.
17. Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J. Surg. 2007; 31: 1256-1263.
18. Jarnagin WR, Ruo L, Little SA etal. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 2003; 98: 1689-1700.
19. Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J. Clin. Oncol. 2012; 30: 1934-1940.
20. Anderson CD, Pinson CW, Berlin J, Chari RS. Diagnosis and treatment of cholangiocarcinoma. Oncologist 2004; 9: 43-57.
21. Valle J, Wasan H, Palmer DH etal. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 2010; 362: 1273-1281.
22. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010; 10: 116-129.
23. Korc M, Friesel RE. The role of fibroblast growth factors in tumor growth. Curr. Cancer Drug Targets 2009; 9: 639-651.
24. Dailey L, Ambrosetti D, Mansukhani A, Basilico C. Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev. 2005; 16: 233-247.
25. Bryant DM, Stow JL. Nuclear translocation of cell-surface receptors: lessons from fibroblast growth factor. Traffic 2005; 6: 947-954.
26. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin. Cancer Res. 2012; 18: 1855-1862.
27. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005; 16: 159-178.
28. Qian X, Anzovino A, Kim S etal. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene 2014; 33: 3411-3421.
29. Tomlinson DC, Baxter EW, Loadman PM, Hull MA, Knowles MA. FGFR1-induced epithelial to mesenchymal transition through MAPK/PLCgamma/COX-2-mediated mechanisms. PLoS One 2012; 7: e38972.
30. Rieke D, Zuo Z, Chawla A etal. Effect of FGFR1 on epithelial-mesenchymal transition and EGFR resistance in HNC: a systems biology approach. ASCO Meeting Abstracts 2014; 32: 6091.
31. Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol. Cancer Res. 2012; 10: 1294-1305.
32. Liu Z, Neiss N, Zhou S etal. Identification of a fibroblast growth factor receptor 1 splice variant that inhibits pancreatic cancer cell growth. Cancer Res. 2007; 67: 2712-2719.
33. Ricol D, Cappellen D, El Marjou A etal. Tumour suppressive properties of fibroblast growth factor receptor 2-IIIb in human bladder cancer. Oncogene 1999; 18: 7234-7243.
34. Narong S, Leelawat K. Basic fibroblast growth factor induces cholangiocarcinoma cell migration via activation of the MEK1/2 pathway. Oncol. Lett. 2011; 2: 821-825.
35. Ogasawara S, Yano H, Higaki K etal. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol. Res. 2001; 20: 97-113.
36. Arai Y, Totoki Y, Hosoda F etal. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology 2014; 59: 1427-1434.
37. Ross JS, Wang K, Gay L etal. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 2014; 19: 235-242.
38. Sia D, Losic B, Cabellos L etal. Discovery of novel mutations and fusion proteins in intrahepatic cholangiocarcinoma. J. Hepatol. 2014; 60: S41. [abstract O-019].
39. Wu YM, Su F, Kalyana-Sundaram S etal. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013; 3: 636-647.
40. Graham RP, Barr Fritcher EG, Pestova E etal. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. Hum. Pathol. 2014; 45: 1630-1638.
41. Xu YF, Yang XQ, Lu XF etal. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma. Biochem. Biophys. Res. Commun. 2014; 446: 54-60.
42. Dieci MV, Arnedos M, Andre F, Soria JC. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013; 3: 264-279.
43. Guagnano V, Kauffmann A, Wohrle S etal. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012; 2: 1118-1133.
44. Lang SA, Scheller T, Moser C etal. Targeting FGFR system in a model of HCC. AACR Annual Meeting Abstracts 2012; Abstract 4373.
45. Nogova L, Sequist LV, Cassier PA etal. Targeting FGFR1-amplified lung squamous cell carcinoma with the selective pan-FGFR inhibitor BGJ398. ASCO Meeting Abstracts 2014; 32: 8034.
46. Bahleda R, Dienstmann R, Adamo B etal. Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts 2014; 32: 2501.
47. Bhide RS, Cai ZW, Zhang YZ etal. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2, 1-f][1, 2, 4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J. Med. Chem. 2006; 49: 2143-2146.
48. Johnson PJ, Qin S, Park JW etal. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J. Clin. Oncol. 2013; 31: 3517-3524.
49. Llovet JM, Decaens T, Raoul JL etal. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J. Clin. Oncol. 2013; 31: 3509-3516.
50. Hilberg F, Roth GJ, Krssak M etal. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008; 68: 4774-4782.
51. Tai WT, Shiau CW, Li YS etal. Nintedanib (BIBF-1120) inhibits hepatocellular carcinoma growth independent of angiokinase activity. J. Hepatol. 2014; 61: 89-97.
52. Kudo K, Arao T, Tanaka K etal. Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo. Clin. Cancer Res. 2011; 17: 1373-1381.
53. Mross K, Stefanic M, Gmehling D etal. Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. Clin. Cancer Res. 2010; 16: 311-319.
54. Kumar R, Knick VB, Rudolph SK etal. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol. Cancer Ther. 2007; 6: 2012-2021.
55. Zhu XD, Zhang JB, Fan PL etal. Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography. BMC Cancer 2011; 11: 28-2407-11-28.
56. Yau T, Chen PJ, Chan P etal. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin. Cancer Res. 2011; 17: 6914-6923.
57. Plummer R, Madi A, Jeffels M etal. A phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2013; 71: 93-101.
58. Wilhelm SM, Dumas J, Adnane L etal. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer 2011; 129: 245-255.
59. Carr BI, Cavallini A, Lippolis C etal. Fluoro-sorafenib (regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J. Cell. Physiol. 2013; 228: 292-297.
60. Bruix J, Tak WY, Gasbarrini A etal. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur. J. Cancer 2013; 49: 3412-3419.
61. Lee SH, Lopes de Menezes D, Vora J etal. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin. Cancer Res. 2005; 11: 3633-3641.
62. Angevin E, Lin C, Pande AU etal. A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: phase I results. J. Clin. Oncol. 2010; 28: abstr 3057.
63. Tai WT, Cheng AL, Shiau CW etal. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Mol. Cancer Ther. 2012; 11: 452-463.
64. Chan SL, Wong CH, Lau CP etal. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2013; 71: 1417-1425.
65. Fetterly GJ, Pitzonka L, Zhao Y etal. A phase I study to assess the safety, tolerability, and PK of dovitinib (D) in combination with gemcitabine (G) and capecitabine (C) in patients with advanced solid tumors. J. Clin. Oncol. 2014; 32 (Suppl.): abstr 2603.
66. O'Hare T, Shakespeare WC, Zhu X etal. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
67. Gozgit JM, Wong MJ, Moran L etal. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012; 11: 690-699.
68. Matsui J, Yamamoto Y, Funahashi Y etal. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int. J. Cancer 2008; 122: 664-671.
69. Okita K, Kumada H, Ikeda K etal. Phase I/II study of E7080 (lenvatinib), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC): initial assessment of response rate. ASCO Meeting Abstracts 2012; 30: 320.
70. Laird AD, Vajkoczy P, Shawver LK etal. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000; 60: 4152-4160.
71. Kanai F, Yoshida H, Tateishi R etal. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother. Pharmacol. 2011; 67: 315-324.
72. Inaba Y, Kanai F, Aramaki T etal. A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Eur. J. Cancer 2013; 49: 2832-2840.
73. French DM, Lin BC, Wang M etal. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One 2012; 7: e36713.
74. Baselga J, Gelmon KA, Verma S etal. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010; 28: 1138-1144.
75. Flaherty KT, Infante JR, Daud A etal. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 2012; 367: 1694-1703.